3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Multiple Myeloma
5
Waldenstrom Macroglobulinemia
1
Recurrence
1
Precancerous Conditions
1
Neoplasms, Plasma Cell
1
Medulloblastoma
1
Mastocytosis, Systemic
1
Lymphoma, Mantle-Cell
1
Liver Neoplasms
1
Leukemia, Large Granular Lymphocytic
1
Ependymoma
1
Carcinoma, Hepatocellular
1
Interventions
lutetium Lu 177 dotatate
20
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Specimen Handling
7
Everolimus
7
cabozantinib
6
Nivolumab
6
lenvatinib
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
surufatinib
4
amino-acid, glucose, and electrolyte solution
4
Capecitabine
4
olaparib
3
lanreotide
3
atezolizumab
3
Temozolomide
3
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Thalidomide
×
1 year
×
Clear all
No trials found.